Anti-Ia reactivity in sera from patients with systemic lupus erythematosus

K. Okudaira, R. P. Searles, J. L. Ceuppens, James Goodwin, R. C. Williams

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Antileukocyte antibodies in sera from patients with systemic lupus erythematosus (SLE) were characterized by determining cross-reacting specificities with the antigens defined by OKT3, OKT4, OKT8, OKM1 and anti-Ia hybridoma antibodies (Abs). T cells were prepared by sheep erythrocyte (E) rosetting after removal of adherent cells. T cells, or non-T cells, were preincubated with SLE sera at 4°C and then with monoclonal Abs. Binding by specific monoclonal Abs was assessed by two methods: rosetting with ox erythrocytes conjugated with goat anti-mouse IgG and also in the fluorescence-activated cell sorter using fluorescein isothiocyanate-conjugated goat anti-mouse IgG. Using the rosetting method, we found that sera from SLE can block the binding of monoclonal mouse hybridoma anti-Ia Abs to T cells; the blocking of other monoclonal Abs was not consistent. Using fluorescence-activated cell sorter analysis, preincubation with SLE sera lowered the intensity of staining and total percentage of either T or non-T cells stained by monoclonal anti-Ia Abs. Blocking of anti-Ia Abs binding by SLE sera was not histocompatibility leukocyte antigen (HLA)-DR restricted and was not due to Fc receptor binding. These results indicated that antibodies in SLE sera react with structures contiguous to or identical with Ia determinants. Anti-Ia activities in SLE sera correlate with SLE disease activity. In addition, there was a significant negative correlation between anti-Ia blocking activity in the sera and the percentage of Ia-positive T cells in the blood of SLE patients. Antibodies in SLE sera with anti-Ia blocking activity may play an important role in immune dysregulation in SLE patients.

Original languageEnglish (US)
Pages (from-to)17-24
Number of pages8
JournalJournal of Clinical Investigation
Volume69
Issue number1
StatePublished - 1982
Externally publishedYes

Fingerprint

Systemic Lupus Erythematosus
Serum
Monoclonal Antibodies
T-Lymphocytes
Anti-Idiotypic Antibodies
Antibodies
Hybridomas
Goats
Erythrocytes
Fluorescence
Muromonab-CD3
Histocompatibility Antigens
Fc Receptors
HLA Antigens
Fluorescein
Sheep
Staining and Labeling
Antigens

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Okudaira, K., Searles, R. P., Ceuppens, J. L., Goodwin, J., & Williams, R. C. (1982). Anti-Ia reactivity in sera from patients with systemic lupus erythematosus. Journal of Clinical Investigation, 69(1), 17-24.

Anti-Ia reactivity in sera from patients with systemic lupus erythematosus. / Okudaira, K.; Searles, R. P.; Ceuppens, J. L.; Goodwin, James; Williams, R. C.

In: Journal of Clinical Investigation, Vol. 69, No. 1, 1982, p. 17-24.

Research output: Contribution to journalArticle

Okudaira, K, Searles, RP, Ceuppens, JL, Goodwin, J & Williams, RC 1982, 'Anti-Ia reactivity in sera from patients with systemic lupus erythematosus', Journal of Clinical Investigation, vol. 69, no. 1, pp. 17-24.
Okudaira, K. ; Searles, R. P. ; Ceuppens, J. L. ; Goodwin, James ; Williams, R. C. / Anti-Ia reactivity in sera from patients with systemic lupus erythematosus. In: Journal of Clinical Investigation. 1982 ; Vol. 69, No. 1. pp. 17-24.
@article{05cdd2124b694f99a1472cc422304cf8,
title = "Anti-Ia reactivity in sera from patients with systemic lupus erythematosus",
abstract = "Antileukocyte antibodies in sera from patients with systemic lupus erythematosus (SLE) were characterized by determining cross-reacting specificities with the antigens defined by OKT3, OKT4, OKT8, OKM1 and anti-Ia hybridoma antibodies (Abs). T cells were prepared by sheep erythrocyte (E) rosetting after removal of adherent cells. T cells, or non-T cells, were preincubated with SLE sera at 4°C and then with monoclonal Abs. Binding by specific monoclonal Abs was assessed by two methods: rosetting with ox erythrocytes conjugated with goat anti-mouse IgG and also in the fluorescence-activated cell sorter using fluorescein isothiocyanate-conjugated goat anti-mouse IgG. Using the rosetting method, we found that sera from SLE can block the binding of monoclonal mouse hybridoma anti-Ia Abs to T cells; the blocking of other monoclonal Abs was not consistent. Using fluorescence-activated cell sorter analysis, preincubation with SLE sera lowered the intensity of staining and total percentage of either T or non-T cells stained by monoclonal anti-Ia Abs. Blocking of anti-Ia Abs binding by SLE sera was not histocompatibility leukocyte antigen (HLA)-DR restricted and was not due to Fc receptor binding. These results indicated that antibodies in SLE sera react with structures contiguous to or identical with Ia determinants. Anti-Ia activities in SLE sera correlate with SLE disease activity. In addition, there was a significant negative correlation between anti-Ia blocking activity in the sera and the percentage of Ia-positive T cells in the blood of SLE patients. Antibodies in SLE sera with anti-Ia blocking activity may play an important role in immune dysregulation in SLE patients.",
author = "K. Okudaira and Searles, {R. P.} and Ceuppens, {J. L.} and James Goodwin and Williams, {R. C.}",
year = "1982",
language = "English (US)",
volume = "69",
pages = "17--24",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - Anti-Ia reactivity in sera from patients with systemic lupus erythematosus

AU - Okudaira, K.

AU - Searles, R. P.

AU - Ceuppens, J. L.

AU - Goodwin, James

AU - Williams, R. C.

PY - 1982

Y1 - 1982

N2 - Antileukocyte antibodies in sera from patients with systemic lupus erythematosus (SLE) were characterized by determining cross-reacting specificities with the antigens defined by OKT3, OKT4, OKT8, OKM1 and anti-Ia hybridoma antibodies (Abs). T cells were prepared by sheep erythrocyte (E) rosetting after removal of adherent cells. T cells, or non-T cells, were preincubated with SLE sera at 4°C and then with monoclonal Abs. Binding by specific monoclonal Abs was assessed by two methods: rosetting with ox erythrocytes conjugated with goat anti-mouse IgG and also in the fluorescence-activated cell sorter using fluorescein isothiocyanate-conjugated goat anti-mouse IgG. Using the rosetting method, we found that sera from SLE can block the binding of monoclonal mouse hybridoma anti-Ia Abs to T cells; the blocking of other monoclonal Abs was not consistent. Using fluorescence-activated cell sorter analysis, preincubation with SLE sera lowered the intensity of staining and total percentage of either T or non-T cells stained by monoclonal anti-Ia Abs. Blocking of anti-Ia Abs binding by SLE sera was not histocompatibility leukocyte antigen (HLA)-DR restricted and was not due to Fc receptor binding. These results indicated that antibodies in SLE sera react with structures contiguous to or identical with Ia determinants. Anti-Ia activities in SLE sera correlate with SLE disease activity. In addition, there was a significant negative correlation between anti-Ia blocking activity in the sera and the percentage of Ia-positive T cells in the blood of SLE patients. Antibodies in SLE sera with anti-Ia blocking activity may play an important role in immune dysregulation in SLE patients.

AB - Antileukocyte antibodies in sera from patients with systemic lupus erythematosus (SLE) were characterized by determining cross-reacting specificities with the antigens defined by OKT3, OKT4, OKT8, OKM1 and anti-Ia hybridoma antibodies (Abs). T cells were prepared by sheep erythrocyte (E) rosetting after removal of adherent cells. T cells, or non-T cells, were preincubated with SLE sera at 4°C and then with monoclonal Abs. Binding by specific monoclonal Abs was assessed by two methods: rosetting with ox erythrocytes conjugated with goat anti-mouse IgG and also in the fluorescence-activated cell sorter using fluorescein isothiocyanate-conjugated goat anti-mouse IgG. Using the rosetting method, we found that sera from SLE can block the binding of monoclonal mouse hybridoma anti-Ia Abs to T cells; the blocking of other monoclonal Abs was not consistent. Using fluorescence-activated cell sorter analysis, preincubation with SLE sera lowered the intensity of staining and total percentage of either T or non-T cells stained by monoclonal anti-Ia Abs. Blocking of anti-Ia Abs binding by SLE sera was not histocompatibility leukocyte antigen (HLA)-DR restricted and was not due to Fc receptor binding. These results indicated that antibodies in SLE sera react with structures contiguous to or identical with Ia determinants. Anti-Ia activities in SLE sera correlate with SLE disease activity. In addition, there was a significant negative correlation between anti-Ia blocking activity in the sera and the percentage of Ia-positive T cells in the blood of SLE patients. Antibodies in SLE sera with anti-Ia blocking activity may play an important role in immune dysregulation in SLE patients.

UR - http://www.scopus.com/inward/record.url?scp=0020082395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020082395&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 17

EP - 24

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -